 |
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
|
PDB id:
|
 |
|
 |
| Name: |
 |
Transferase
|
 |
|
Title:
|
 |
Human liver glycogen phosphorylase a complexed with riboflav acetyl-beta-d-glucopyranosylamine and cp-403,700
|
|
Structure:
|
 |
Glycogen phosphorylase, liver form. Chain: a, b. Synonym: glycogen phosphorylase a. Engineered: yes
|
|
Source:
|
 |
Homo sapiens. Human. Organism_taxid: 9606. Organ: liver. Expressed in: escherichia coli. Expression_system_taxid: 562
|
|
Biol. unit:
|
 |
Dimer (from PDB file)
|
|
Resolution:
|
 |
|
2.10Å
|
R-factor:
|
0.247
|
R-free:
|
0.283
|
|
|
Authors:
|
 |
J.L.Ekstrom,T.A.Pauly,M.D.Carty,W.C.Soeller,J.Culp,D.E.Danle D.J.Hoover,J.L.Treadway,E.M.Gibbs,R.J.Fletterick,Y.S.N.Day, D.G.Myszka,V.L.Rath
|
Key ref:
|
 |
J.L.Ekstrom
et al.
(2002).
Structure-activity analysis of the purine binding site of human liver glycogen phosphorylase.
Chem Biol,
9,
915-924.
PubMed id:
DOI:
|
 |
|
Date:
|
 |
|
07-Mar-02
|
Release date:
|
04-Dec-02
|
|
|
|
|
|
PROCHECK
|
|
|
|
|
Headers
|
 |
|
|
References
|
|
|
|
|
|
|
|
|
|
P06737
(PYGL_HUMAN) -
Glycogen phosphorylase, liver form
|
|
|
|
Seq: Struc:
|
 |
 |
 |
847 a.a.
790 a.a.
|
|
|
|
|
|
|
 |
 |
|
|
Key: |
 |
PfamA domain |
 |
 |
 |
Secondary structure |
 |
 |
CATH domain |
 |
|
|
|
|
 |
|
|
 |
 |
 |
 |
Enzyme class:
|
 |
E.C.2.4.1.1
- Phosphorylase.
|
|
 |
 |
 |
 |
 |

Pathway:
|
 |
Glycogen
|
 |
 |
 |
 |
 |
Reaction:
|
 |
(1,4-alpha-D-glucosyl)(n) + phosphate = (1,4-alpha-D-glucosyl)(n-1) + alpha-D-glucose 1-phosphate
|
 |
 |
 |
 |
 |
(1,4-alpha-D-glucosyl)(n)
Bound ligand (Het Group name = )
matches with 55.56% similarity
|
+
|
phosphate
|
=
|
(1,4-alpha-D-glucosyl)(n-1)
|
+
|
alpha-D-glucose 1-phosphate
Bound ligand (Het Group name = )
matches with 63.16% similarity
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Molecule diagrams generated from .mol files obtained from the
KEGG ftp site
|
|
 |
 |
|
 |
|
 |
|
|
Gene Ontology (GO) functional annotation
|
|
|
|
 |
 |
 |
|
 |
 |
 |
 |
|
 |
|
Cellular component
|
soluble fraction
|
3 terms
|
 |
|
Biological process
|
metabolic process
|
7 terms
|
 |
|
Biochemical function
|
catalytic activity
|
16 terms
|
 |
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
|
| |
|
DOI no:
|
Chem Biol
9:915-924
(2002)
|
|
PubMed id:
|
|
|
|
|
| |
|
Structure-activity analysis of the purine binding site of human liver glycogen phosphorylase.
|
|
J.L.Ekstrom,
T.A.Pauly,
M.D.Carty,
W.C.Soeller,
J.Culp,
D.E.Danley,
D.J.Hoover,
J.L.Treadway,
E.M.Gibbs,
R.J.Fletterick,
Y.S.Day,
D.G.Myszka,
V.L.Rath.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
Human liver glycogen phosphorylase (HLGP) catalyzes the breakdown of glycogen to
maintain serum glucose levels and is a therapeutic target for diabetes. HLGP is
regulated by multiple interacting allosteric sites, each of which is a potential
drug binding site. We used surface plasmon resonance (SPR) to screen for
compounds that bind to the purine allosteric inhibitor site. We determined the
affinities of a series of compounds and solved the crystal structures of three
representative ligands with K(D) values from 17-550 microM. The crystal
structures reveal that the affinities are partly determined by ligand-specific
water-mediated hydrogen bonds and side chain movements. These effects could not
be predicted; both crystallographic and SPR studies were required to understand
the important features of binding and together provide a basis for the design of
new allosteric inhibitors targeting this site.
|
|
|
|
|
| |
Selected figure(s)
|
|
|
| |
 |
 |
|
 |
|
 |
Figure 2.
Figure 2. Purine Site ScreenFor each of the 18 compounds
tested, the RU values at equilibrium versus ligand concentration
were fitted to a 1:1 interaction model. The resulting fitted
curves are superimposed and listed in order on the right
starting from the curve closest to the upper left (riboflavin)
to the curve closest to the lower right (allantoin), with the
labels color coded to match their respective binding isotherms.
For clarity, only the curves for riboflavin, caffeine, and uric
acid are labeled directly.
|
 |
Figure 3.
Figure 3. Crystal Structure of HLGPa/Purine Site
Ligands(A), Uric acid bound at the purine site; (B), caffeine
bound at the purine site; (C), riboflavin bound at the purine
site. The 2F[o]-F[c] difference electron density for each ligand
is contoured at 1σ above the mean. The figures were prepared
using Ribbons [31], and each panel is colored as follows:
structural elements of the N-terminal domain, red; those of the
C-terminal domain, blue; oxygen atoms, red; nitrogen atoms,
blue; carbon atoms, green; and water molecules are shown as red
spheres.
|
 |
|
|
|
| |
The above figures are
reprinted
by permission from Cell Press:
Chem Biol
(2002,
9,
915-924)
copyright 2002.
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
G.Chessari,
and
A.J.Woodhead
(2009).
From fragment to clinical candidate--a historical perspective.
|
| |
Drug Discov Today, 14,
668-675.
|
 |
|
|
|
|
 |
A.Pautsch,
N.Stadler,
O.Wissdorf,
E.Langkopf,
W.Moreth,
and
R.Streicher
(2008).
Molecular recognition of the protein phosphatase 1 glycogen targeting subunit by glycogen phosphorylase.
|
| |
J Biol Chem, 283,
8913-8918.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
K.M.Alexacou,
J.M.Hayes,
C.Tiraidis,
S.E.Zographos,
D.D.Leonidas,
E.D.Chrysina,
G.Archontis,
N.G.Oikonomakos,
J.V.Paul,
B.Varghese,
and
D.Loganathan
(2008).
Crystallographic and computational studies on 4-phenyl-N-(beta-D-glucopyranosyl)-1H-1,2,3-triazole-1-acetamide, an inhibitor of glycogen phosphorylase: comparison with alpha-D-glucose, N-acetyl-beta-D-glucopyranosylamine and N-benzoyl-N'-beta-D-glucopyranosyl urea binding.
|
| |
Proteins, 71,
1307-1323.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
L.L.Lairson,
B.Henrissat,
G.J.Davies,
and
S.G.Withers
(2008).
Glycosyltransferases: structures, functions, and mechanisms.
|
| |
Annu Rev Biochem, 77,
521-555.
|
 |
|
|
|
|
 |
C.M.Lukacs,
N.G.Oikonomakos,
R.L.Crowther,
L.N.Hong,
R.U.Kammlott,
W.Levin,
S.Li,
C.M.Liu,
D.Lucas-McGady,
S.Pietranico,
and
L.Reik
(2006).
The crystal structure of human muscle glycogen phosphorylase a with bound glucose and AMP: an intermediate conformation with T-state and R-state features.
|
| |
Proteins, 63,
1123-1126.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
A.W.Schüttelkopf,
and
D.M.van Aalten
(2004).
PRODRG: a tool for high-throughput crystallography of protein-ligand complexes.
|
| |
Acta Crystallogr D Biol Crystallogr, 60,
1355-1363.
|
 |
|
|
|
|
 |
M.N.Kosmopoulou,
D.D.Leonidas,
E.D.Chrysina,
N.Bischler,
G.Eisenbrand,
C.E.Sakarellos,
R.Pauptit,
and
N.G.Oikonomakos
(2004).
Binding of the potential antitumour agent indirubin-5-sulphonate at the inhibitor site of rabbit muscle glycogen phosphorylase b. Comparison with ligand binding to pCDK2-cyclin A complex.
|
| |
Eur J Biochem, 271,
2280-2290.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
R.L.Rich,
and
D.G.Myszka
(2003).
A survey of the year 2002 commercial optical biosensor literature.
|
| |
J Mol Recognit, 16,
351-382.
|
 |
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
code is
shown on the right.
|
|